Home  /  Resource Library  /  Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial

Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial

Study examined genetic biomarkers associated with resistance to ibrutinib for treatment of relapsed follicular lymphoma.